[HTML][HTML] Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline …
HJ Burstein, S Temin, H Anderson… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
HJ Burstein, S Temin, H Anderson, TA Buchholz, NE Davidson, KE Gelmon, SH Giordano…
Journal of clinical oncology, 2014•ncbi.nlm.nih.govPurpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy on
the basis of emerging data on the optimal duration of treatment, particularly adjuvant
tamoxifen. Methods ASCO convened the Update Committee and conducted a systematic
review of randomized clinical trials from January 2009 to June 2013 and analyzed three
historical trials. Guideline recommendations were based on the Update Committee's review
of the evidence. Outcomes of interest included survival, disease recurrence, and adverse …
the basis of emerging data on the optimal duration of treatment, particularly adjuvant
tamoxifen. Methods ASCO convened the Update Committee and conducted a systematic
review of randomized clinical trials from January 2009 to June 2013 and analyzed three
historical trials. Guideline recommendations were based on the Update Committee's review
of the evidence. Outcomes of interest included survival, disease recurrence, and adverse …
Abstract
Purpose
To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen.
Methods
ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events.
Results
This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer.
ncbi.nlm.nih.gov